UPDATE 1-AstraZeneca won't file Recentin for colon cancer
LONDON, May 28 (Reuters) - AstraZeneca (AZN.L) dropped plans to file its experimental cancer drug Recentin as a first-line treatment for colon cancer on Friday after disappointing results from a second pivotal clinical trial with the medicine.The latest Phase III clinical trial, known as Horizon II, showed Recentin improved progression-free survival but there was no improvement in overall survival.
The drug, also known as cediranib, had already failed in another study comparing it head-to-head with Roche's (ROG.VX) blockbuster Avastin in March.
"Based on the results of these two trials, AstraZeneca does not intend to file regulatory submissions in first-line mCRC (metastatic colorectal cancer)," the company said.
The drug may still have a role in different cancer types, however. Results of a Phase III study evaluating in treating recurrent glioblastoma, a brain cancer, are expected soon and AstraZeneca is also examining whether it may have applications in a number of other tumour types. (Reporting by Ben Hirschler; Editing by Dan Lalor)
*We welcome comments that advance the story directly or with relevant tangential information. We try to block comments that use offensive language or appear to be spam and review comments frequently to ensure they meet our standards. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters.
Friday, May 28, 2010
Clinical trials - ain't they a bitch!
via uk.reuters.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment